Arbutus Biopharma Shares Outstanding 2008-2021 | ABUS

Arbutus Biopharma shares outstanding from 2008 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Arbutus Biopharma Annual Shares Outstanding
(Millions of Shares)
2020 76
2019 57
2018 55
2017 55
2016 53
2015 45
2014 22
2013 15
2012 14
2011 11
2010 10
2009 52
2008 41
2007 24
Arbutus Biopharma Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 97
2021-03-31 93
2020-12-31 76
2020-09-30 79
2020-06-30 70
2020-03-31 68
2019-12-31 57
2019-09-30 57
2019-06-30 57
2019-03-31 56
2018-12-31 55
2018-09-30 55
2018-06-30 56
2018-03-31 55
2017-12-31 55
2017-09-30 55
2017-06-30 55
2017-03-31 54
2016-12-31 53
2016-09-30 54
2016-06-30 53
2016-03-31 51
2015-12-31 45
2015-09-30 51
2015-06-30 54
2015-03-31 30
2014-12-31 22
2014-09-30 22
2014-06-30 22
2014-03-31 20
2013-12-31 17
2013-09-30 15
2013-06-30 14
2013-03-31 14
2012-12-31 15
2012-09-30 14
2012-06-30 14
2012-03-31 13
2011-12-31 12
2011-09-30 12
2011-06-30 11
2011-03-31 10
2010-12-31 9
2010-09-30 10
2010-06-30 53
2010-03-31 49
2009-12-31 52
2009-09-30 56
2009-06-30 57
2009-03-31 52
2008-12-31 44
2008-09-30 52
2008-06-30 34
2008-03-31 25
2007-12-31 41
2007-09-30 25
2007-06-30 25
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.408B $0.007B
Arbutus Biopharma Corporation is a biopharmaceutical company which is focused on discovering, developing and commercializing a portfolio of drug candidates for chronic hepatitis B infection. The Company's products include TKM-HBV, Cyclophilin Inhibitor-OCB-030, TLR9 Agonist (CYT-003), Capsid Assembly Inhibitors, Surface Antigen Secretion Inhibitors, STING Agonists, cccDNA Formation Inhibitors, cccDNA Epigenetic Modifiers, TKM-PLK1, GI-NET and ACC, HCC, TKM-Ebola, TKM-Ebola-Guinea, TKM-Marburg, TKM-HTG and TKM-ALDH which are in different clinical trial stage. Arbutus Biopharma Corp, formerly known as Tekmira Pharmaceuticals Corporation, is headquartered in Vancouver, BC.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57